Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

6.13
-0.2100-3.31%
Post-market: 6.230.1000+1.63%19:30 EDT
Volume:835.40K
Turnover:5.21M
Market Cap:118.56M
PE:-1.01
High:6.68
Open:6.59
Low:6.06
Close:6.34
52wk High:20.56
52wk Low:6.06
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.12
T/O Rate:4.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.16
PE(LYR):-1.04

Loading ...

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
7 hours ago

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 01

Corbus Pharmaceuticals Announces First Patient Dosed in Tempo-1 Registrational Study of Crb-701 in Patients with 2L+ Oropharyngeal Cancer

THOMSON REUTERS
·
Sep 29

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Sep 29

Corbus Pharmaceuticals Holdings Inc. Stock Sheds 4.2%, Underperforms Peers

Dow Jones
·
Sep 26

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 24

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 19

Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers

Dow Jones
·
Sep 17

Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers

Dow Jones
·
Sep 16

Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Sep 15

Analysts’ Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

TIPRANKS
·
Sep 15

Corbus Pharmaceuticals Price Target Maintained with a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 15

Corbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Corbus Pharma Reports Positive Top-Line Data from Weight-Loss Drug Study

Dow Jones
·
Sep 14

Corbus Says Phase 1b Canyon-1 Trial Shows CRB-913 Delivers 5% Mean Weight Loss at 12 Weeks in Obesity Study

Reuters
·
Sep 14

Corbus Pharmaceuticals Holdings, - Expects to Initiate Phase 2 Monotherapy Study for Crb-913 in H1 2027

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Announces Positive Topline Data from Canyon-1 Study of Daily Oral Crb-913 for the Treatment of Obesity

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Holdings, - Crb-913 Treatment Discontinuations Due to Adverse Events Range from 3.1% to 13.1%

THOMSON REUTERS
·
Sep 14